We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 656

Rx IP update 2015 mid-year highlights
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • July 16 2015

The following is a mid-year review of the top IP and regulatory law developments in life sciences in Canada. 1. Still no clarification from Supreme

The top 5 trends in Canadian intellectual property law for 2015
  • Bennett Jones LLP
  • Canada
  • March 3 2015

Last year promised significant changes in Canadian IP law; some of which will be realized in 2015. As the first quarter draws to a close, this year's

Industry news
  • Borden Ladner Gervais LLP
  • Canada
  • December 16 2014

The Patented Medicine Prices Review Board (PMPRB) has released a new report titled "Generic Drugs in Canada, 2013", which compares the prices of

Intellectual property weekly abstracts bulletin week of August 18
  • Borden Ladner Gervais LLP
  • Canada
  • August 20 2014

In this case, Apotex sought to enter the market with its generic version of travoprost. The Court dismissed the proceeding on the basis that Apotex’

Federal court affirms standing for innovative drug manufacturer
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 23 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the

Competition Bureau turns its focus to IP rights in the pharmaceutical industry
  • Baker & McKenzie
  • Canada
  • May 13 2014

Following trends towards increased enforcement activity and a heightened focus on intellectual property in the pharmaceutical industry, the

Other industry news
  • Borden Ladner Gervais LLP
  • Canada
  • May 5 2014

The amendments to the Patent Rules and Trade-marks Regulations affecting both patent and trade-mark agents came into effect on May 1, 2014. The

IP in the life sciences industries 2013
  • Intellectual Asset Management
  • Canada, Germany, India, Mexico, Sweden, USA
  • May 24 2013

No matter what stage of the business cycle they have reached, it is critical for companies in the life sciences sector to identify, protect and

Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • United Kingdom, USA, Australia, Canada, European Union
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Data protection: defining innovative drug in Canada
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994